iPierian
AcquiredSouth San Francisco, United States · Founded 2008
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2008
- Business Model
- B2B
- Website
- bms.com
- Last Round
- Series CSep 2013
- Rounds
- 3
About
iPierian (formerly iZumi Bio) was a South San Francisco biopharmaceutical company founded in 2008 that pioneered the use of induced pluripotent stem cell (iPSC) technology to model and develop therapies for neurodegenerative diseases, including ALS and tauopathies. The company was acquired by Bristol-Myers Squibb in 2014 for up to $725 million.
Summary
iPierian is a Biotech company based in South San Francisco, United States, founded in 2008. Its most recent funding was a Series C round in Sep 2013. Investors include SR One, Kleiner Perkins and MPM Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2014
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...